Lv62
1690 积分 2023-09-24 加入
Strong CD8(+) T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma
30天前
已完结
Cancer immunotherapy using checkpoint blockade
30天前
已完结
The B7:CD28 family and friends: Unraveling coinhibitory interactions
30天前
已完结
Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer
1个月前
已完结
Inhibition of myeloid PD-L1 suppresses osteoclastogenesis and cancer bone metastasis
1个月前
已完结
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
1个月前
已完结
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
1个月前
已完结
PD-1 and cancer: molecular mechanisms and polymorphisms
1个月前
已完结
On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial
1个月前
已完结
Transplant renal artery stenosis: Study of incidence using doppler ultrasound, risk factors and analysis effect in graft outcomes
2个月前
已完结
皖公网安备34019202002308
